Mark E. Robson Discusses When Genetic Testing Is Needed
Mark E. Robson, MD, Clinical Director of the Clinical Genetics Services at Memorial Sloan Kettering Cancer Center, discusses when it is appropriate to go for genetic testing to determine cancer risk.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512